Novakand Pharma AB (publ) (LARK) — Cash Flow Reinvestment Rate
Novakand Pharma AB (publ) (LARK) has a Cash Flow Reinvestment Rate of 0.00x as of September 2022, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr379.00K. For the full cash flow conversion analysis, see LARK cash generation efficiency.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Novakand Pharma AB (publ) Cash Flow Reinvestment Rate (2012–2021)
Historical reinvestment intensity for Novakand Pharma AB (publ) across 3 annual periods. See LARK financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow Reinvestment Rate for Novakand Pharma AB (publ) (2012–2021)
Year-by-year capital reinvestment analysis for Novakand Pharma AB (publ). See Novakand Pharma AB (publ) free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.01x | Skr147.73K | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr430.20K | Skr227.60K | Skr430.20K | — |
| 2012 | 0.00x | Skr0.00 | Skr59.21K | Skr0.00 | — |